Clinical Trial

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
Trial Details
NCT Number NCT05582993
Lead Sponsor Takeda
Conditions Von Willebrand Disease (VWD)
Enrollment 24 participants
Start Date 2024-11-06
Primary Completion 2030-04-11 (estimated)
Study Completion 2030-04-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-27